Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Novartis temporarily halts production of two radioligand therapy medicines

By Brian Buntz | May 6, 2022

Novartis logoNovartis (NYSE:NVS) announced that it had voluntarily stopped the production at radioligand therapy plants in Ivrea, Italy and Millburn, New Jersey, over possible quality concerns.

In a statement, the company explained it had made the decision “out of an abundance of caution due to potential quality issues identified in its manufacturing processes.”

As a result, it will stop the distribution of Lutathera (USAN: lutetium Lu 177 dotatate; INN: lutetium (177Lu) oxodotreotide in the U.S. and Canada, and Pluvicto (lutetium Lu 177 vipivotide tetraxetan).

The company plans to investigate further before resuming the production of the two radioligand therapies.

The company anticipates having some supply of the two drugs in the next six weeks.

In the meantime, the company can continue distributing Lutathera in Europe and Asia from a site in Zaragoza, Spain. Novartis, however, acknowledges that the supply of the drugs may be limited.

The company will also place a temporary hold on screening and enrollment for international clinical trials involving 177Lu-PSMA-617 and Lutathera studies in the U.S. and Canada.

NVS shares fell 0.45% to $85.82 on Friday.

FDA approved Lutathera for gastroenteropancreatic neuroendocrine tumors in 2018.

Pluvicto became FDA approved in March 2022 as a treatment for progressive, PSMA-positive metastatic castration-resistant prostate cancer.

 

Tell Us What You Think! Cancel reply

Related Articles Read More >

Seagen
Seagen CEO Siegall resigns after domestic abuse arrest
Moderna
Moderna’s new CFO leaves after former employer discloses investigation
Pfizer logo
Pfizer to shell out $11.6B for migraine drugmaker Biohaven
Bauch + Lomb
Bausch + Lomb makes its stock market debut

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards